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S U M M A R Y
Background: De-escalation therapy is a strategy used widely to treat infections while avoiding the use of
broad-spectrum antimicrobials. However, there is a paucity of clinical evidence to demonstrate the
effectiveness and safety of de-escalation therapy compared to conventional therapy.
Methods: A systematic review and meta-analysis was conducted on de-escalation therapy for a variety
of infections. A search of the MEDLINE (via PubMed), EMBASE, and Cochrane Library databases up to
July 2015 for relevant studies was performed. The primary outcome was relevant mortality, such as
30-day mortality and in-hospital mortality. A meta-analysis was to be conducted for the pooled
odds ratio using the random-effects model when possible. Both randomized controlled trials and
observational studies were included in the analysis.
Results: A total of 23 studies were included in the analysis. There was no difference in mortality for most
infections, and some studies favored de-escalation over non-de-escalation for better survival. The
quality of most studies included was not high.
Conclusions: This review and analysis suggests that de-escalation therapy is safe and effective for most
infections, although higher quality studies are needed in the future.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The provision of effective antimicrobial therapy in a timely
manner and of an appropriate spectrum is one of the mainstays
of the treatment of infectious diseases.1,2 However, this has led to
the widespread use of broad-spectrum antibiotic therapy for the
empirical treatment of infections, which may have contributed to
the increase in a variety of drug-resistant organisms.
De-escalation therapy is an approach aimed at balancing the
effective treatment of patients with infections and the prevention
of an increase in antimicrobial resistance. It allows the use of
broad-spectrum antimicrobials as empirical therapeutic agents,
but these are replaced by agents with the narrowest possible
spectrum immediately upon identiﬁcation of the causative
organisms and the results of antimicrobial susceptibility testing
.3 Thus failure of the initial therapy of each given infectious disease
is avoided by use of broad-spectrum antibiotics, and they can then* Corresponding author. Tel.: +81-78-382-6296.
E-mail address: kentaroiwata1969@gmail.com (K. Iwata).
http://dx.doi.org/10.1016/j.ijid.2016.06.002
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).be discontinued so that antibiotic pressure to select resistant
organisms is minimized .
The premise justifying the de-escalation strategy is clinical
efﬁcacy and safety that is non-inferior to therapy without de-
escalation. However, there is a paucity of clinical evidence to
demonstrate the equivalence or non-inferiority of de-escalation
therapy compared to conventional therapy. A recent meta-analysis
on de-escalation therapy for adults with sepsis, severe sepsis, or
septic shock by the Cochrane Collaboration sought to include
randomized controlled trials (RCTs), but not a single such study
could be found to include in the analysis.4 However, it should not
be concluded that de-escalation has no value. The Cochrane
Collaboration did not examine infections other than sepsis and
they did not include clinical studies other than RCTs. The inclusion
of observational studies in meta-analyses might impair the
quality of the study, but meta-analyses using observational studies
have provided clinically robust and useful information. In fact,
observational studies may even provide important additional
information or higher-quality evidence than available RCTs for
certain health care problems.5
Therefore, a systematic review and meta-analysis was con-
ducted on de-escalation therapy for a variety of infections, not onlyciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Figure 1. Summary of evidence search and selection.
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tional studies to be included in the analysis.
2. Methods
The primary objective was to evaluate the efﬁcacy and safety of
de-escalation therapy compared to antimicrobial therapy without
de-escalation for a variety of infections by measuring the all-cause
mortality for a certain duration.
De-escalation was deﬁned as a change in the initially
appropriate antimicrobial therapy from an empirical broad-
spectrum characteristic to a narrower-spectrum one (either by
changing the antimicrobial agent or by discontinuing an eventual
antimicrobial combination, or both) according to culture results or
for other clinical reasons.6–8
This systematic review was conducted in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement9 and the Meta-analysis Observa-
tional Studies in Epidemiology (MOOSE) guidelines.10
2.1. Search strategy and study selection
A search of the MEDLINE (via PubMed), EMBASE, and Cochrane
Library databases up to July 2015 for relevant studies was
performed. The reports retrieved were also screened manually
for further potentially relevant articles. No language restriction
was applied. The search strategy is provided in the Appendix.
2.2. Study eligibility criteria
Two investigators (GO and KI) independently screened all
citations by title and abstract. The same investigators then
screened the studies retrieved independently. Disagreements
regarding inclusion were resolved by discussion or by consulting
a third investigator (AD).
Any comparative studies such as RCTs, quasi-experimental
designs, and observational studies that assessed the effectiveness
of the de-escalation therapy strategy were included. Attempts
were made to contact the authors of the studies if necessary.
The primary outcome was 28–30-day mortality, in-hospital
mortality, or other types of mortality if necessary. All-cause
mortality was included, but infection-speciﬁc mortality was not,
since the aim was to evaluate the overall risk/beneﬁt of de-
escalation, taking into account potential factors such as the toxicity
of the medications. A meta-analysis of studies with the same
clinical diagnosis and outcomes was to be conducted if possible.
The GRADE (Grading of Recommendations Assessment, Devel-
opment, and Evaluation) approach for estimating the quality of
evidence was used, utilizing GRADEpro to assess each study.10,11
The completed evidence summaries and GRADE assessments were
discussed by the investigators. The conﬁdence in the estimate of
effect was categorized into four levels, ranging from very low to
high.
2.3. Data synthesis and analysis
For the data synthesis, meta-analyses of dichotomous outcomes
were conducted using Mantel–Haenszel methods with the
random-effects model to provide the odds ratio (OR), utilizing
Review Manager, version 5.3 (The Nordic Cochrane Center and the
Cochrane Collaboration, Copenhagen, Denmark) . All statistical
tests were two-sided, and a p-value of <0.05 was considered to be
statistically signiﬁcant.
Heterogeneity was measured and expressed as I2, the percent-
age of total variation across studies due to between-study
heterogeneity rather than chance, with suggested thresholds forlow (I2 < 49%), moderate (I2 = 50–74%), and high (I2 > 75%)
values.12–14 The funnel plot for mortality was examined visually
to assess publication bias.
3. Results
3.1. Literature ﬂow
A total of 12 627 articles were identiﬁed in the electronic
search of the databases (1862 articles from MEDLINE via
PubMed, 573 articles from the Cochrane Library, and 10 192
articles from EMBASE). After removing duplicate articles, 10 607
remained. The titles and abstracts of these articles were screened
and it was possible to retrieve 90 full-text articles and conference
abstracts. Eleven further articles were found after reviewing
the reference lists of the articles retrieved. Forty-ﬁve compara-
tive studies were then selected out for full-text review. Studies
were excluded for the following reasons: no relevant clinical
outcomes or the outcomes were not evaluated for de-escalation
(n = 8), no full text data were obtainable (n = 8), duplication of
published articles and conference abstracts (n = 3), and the
antimicrobial change was not actually de-escalation by deﬁni-
tion (n = 3). The remaining 23 articles were reviewed for this
study (Figure 1).
3.2. Community-acquired pneumonia (CAP)
Two studies concerning de-escalation for CAP were found.
Kothe et al. conducted a multi-center prospective observational
study in Germany from 2003 to 2005.15 They mainly analyzed the
outcome data of CAP based on patient age groups. However, it was
possible to calculate the outcome (30-day mortality) according to
de-escalation status. Among 2647 patients who participated in the
study, 114 (4%) received de-escalation treatment, whereas the
remaining 2533 (96%) received conventional treatment without
de-escalation.
Carugati et al. analyzed data on hospitalized patients with
bacteremic CAP in 35 countries.16 Among 289 patients whose
initial antimicrobial therapy was considered appropriate on
admission, 165 (57%) received de-escalation therapy and 96
(43%) remained on the initial treatment.
The combined 30-day mortality after meta-analysis was
signiﬁcantly lower in the de-escalation group (Figure 2; OR 0.50,
95% conﬁdence interval (CI) 0.29–0.87).
Figure 2. Forest plot of 30-day mortality for community-acquired pneumonia (CI, conﬁdence interval).
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Kim et al. conducted a prospective open-label randomized
clinical trial at a medical intensive care unit (ICU) in South Korea.17
Patients who were diagnosed and then admitted to the ICU were
enrolled, and were randomized to either a de-escalation group or
a non-de-escalation group. There was no difference in overall
hospital mortality between the groups (44.2% vs. 34.6%, p = 0.316).
This study was peculiar since the initial empirical antimicrobials
differed between the de-escalation group and the non-de-
escalation group. There were more multidrug-resistant organisms
detected after treatment in the de-escalation group, and mortality
from methicillin-resistant Staphylococcus aureus (MRSA) pneumo-
nia was also higher in the de-escalation group.
Khasawneh et al. conducted a retrospective observational study
for bacteremic HAP at a hospital in the USA.18 There was no
difference in overall hospital mortality between groups (9.0% vs.
25.9%, p = 0.09).
Meta-analysis combining these two studies also did not show
a statistical difference in in-hospital mortality between the de-
escalation group and the non-de-escalation group (Figure 3; OR
0.75, 95% CI 0.14–3.96). The studies included showed high
heterogeneity (I2 = 75%).
3.4. ICU-acquired pneumonia
Three studies investigating the effectiveness of de-escalation
for pneumonia that developed in the ICU were found. Most were
cases of ventilator-associated pneumonia (VAP), but not all of
them. Therefore, ICU-acquired pneumonia was analyzed as a
different entity, and VAP is discussed separately (see below).
A´lvarez-Lerma et al. designed a prospective multi-center
observational study in 24 ICUs of Spanish general hospitals.19 A
total of 244 patients were enrolled with diagnostic criteria
developed by the US Centers for Disease Control and Prevention.20Figure 3. Forest plot of in-hospital mortality for hospi
Figure 4. Forest plot of in-hospital mortality for ICUMost patients (83.5%) were on mechanical ventilation. Among the
ﬁve groups of patients in this study, group III represented non-de-
escalation therapy and group IV represented de-escalation therapy.
Joung et al. conducted a retrospective observational study in the
medical and surgical ICU of a tertiary care university hospital in
South Korea.21 The diagnostic criteria were the same as those used
by A´lvarez-Lerma et al. More than 90% of the patients were on
mechanical ventilation. Both pneumonia-related and overall
mortality at day 30 were reported to be signiﬁcantly lower in
the de-escalation group (p = 0.03 and p = 0.04, respectively), but
it was not possible to ﬁnd an actual number of deaths with regard
to overall in-hospital mortality, and thus it was not possible to
include this study in the meta-analysis.
Knaak conducted a retrospective observational study in an ICU
at a tertiary care academic medical center in the USA.22 Both
pneumonia diagnosed in the ICU and in those transferred to the
ICU after diagnosis of health care-associated pneumonia (HCAP)
were included in the study, with adequate diagnostic criteria.
The combined meta-analysis favored de-escalation to decrease
in-hospital mortality (Figure 4; OR 0.34, 95% CI 0.17–0.68).
3.5. Ventilator-associated pneumonia (VAP)
Kollef et al. designed a prospective observational study on VAP
in 20 ICUs in the USA.23 De-escalation occurred in 22.1% of the
patients.
Giantsou et al. also conducted a prospective observational study
on VAP at a university hospital in Greece.24 De-escalation occurred
in 40.5% of the patients.
Joffe et al. performed a secondary analysis in a multi-center trial
of patients with VAP randomized to bronchoscopy or endotracheal
aspirate cultures.25 Among patients with a positive culture from
the lower respiratory tract, the majority went through de-
escalation. Both 28-day mortality and in-hospital mortality were
measured as outcomes.tal-acquired pneumonia (CI, conﬁdence interval).
-acquired pneumonia (CI, conﬁdence interval).
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on VAP diagnosed by quantitative bronchoalveolar lavage at a
surgical ICU in the USA.26
Meta-analyses of both 28-day mortality and in-hospital
mortality did not show a statistical difference between de-
escalation therapy and non-de-escalation therapy (Figure 5; OR
0.49, 95% CI 0.07–3.32 and OR 0.88, 95% CI 0.54–1.44, respectively).
High heterogeneity was observed in the analysis of 28-day
mortality (I2 = 92%).
3.6. Bacteremia
Shime et al. published two retrospective observational studies
on this subject, based on positive blood cultures, at a university
medical center in Japan.27,28 The ﬁrst concerned bacteremia
diagnosed between 2004 and 2009, and there was no difference
in in-hospital mortality between the de-escalation group and the
group of those whose antimicrobials were unchanged or escalated
(1% vs. 5%, p = 0.20).27 The second study concerned bacteremia
caused by speciﬁc Gram-negative bacilli (SPACEs; Serratia,
Pseudomonas, Acinetobacter, Citrobacter, and Enterobacter), diag-
nosed between 2006 and 2011 at the same institution. Again, there
was no difference in in-hospital mortality between the de-
escalation group (0/28 patients) and the non-de-escalation group
(2/11 patients) (p = 0.20).28
Since there was an overlap in the period observed in these two
studies at the same institution, with different clinical entities
evaluated, it was not possible to combine them.
3.7. Urinary tract infection (UTI)
Khasawneh et al. conducted a retrospective observational study
on bacteremic UTI at a hospital in the USA.29 UTI was diagnosed
based on positive blood cultures, urine cultures, and a review of the
medical records. There was a trend in in-hospital mortality
favoring the de-escalation group (1/34 patients) over the non-de-
escalation group (6/31 patients) (p = 0.06).
3.8. Sepsis with bloodstream infection (BSI)
Koupetori et al. conducted a prospective multi-center observa-
tional study on sepsis/BSI in 31 hospitals in Greece.30 Both
community-acquired and hospital-acquired infections were in-
cluded in the study. Inclusion criteria were (1) age 18 years, (2)
systemic inﬂammatory response syndrome (SIRS), and (3)Figure 5. Forest plot of 28-day mortality (A) and in-hospital mortalitypresence of BSI. There were two study periods over which the
effectiveness of antimicrobial treatment was observed (2006–
2009 and 2010–2013). Although Kaplan–Meier survival analysis
demonstrated signiﬁcantly prolonged survival for the de-escala-
tion group during the latter period, Cox regression analysis after
adjustment for disease severity showed no difference in mortality
between the de-escalation group and non-de-escalation group for
both periods (hazard ratio (HR) 2.48, 95% CI 0.75–8.12 and OR 0.69,
95% CI 0.28–1.69, respectively).
3.9. Severe sepsis and/or septic shock
Garnacho-Montero et al. performed a prospective observational
study enrolling patients admitted to the ICU of a university
hospital in Spain with severe sepsis and septic shock.31 A
propensity score-adjusted multivariable analysis was performed,
and the OR for overall mortality adjusted by propensity score
favored de-escalation (adjusted OR 0.55, 95% CI 0.32–0.98).
Leone et al. conducted a multi-center open-label randomized
non-inferiority trial on severe sepsis at nine ICUs in France.32 The
de-escalation group had a signiﬁcantly longer time between sepsis
and inclusion in the study (mean 3.2 days vs. 2.7 days, p = 0.05), but
patients in the non-de-escalation group were signiﬁcantly older
(mean 57.9 years vs. 66.8 years, p = 0.003). There was no difference
in 90-day mortality between the de-escalation group and the non-
de-escalation group (31% vs. 23%, p = 0.35). There was no difference
in other outcomes, such as length of ICU stay.33
The meta-analysis of 90-mortality did not show superiority for
either treatment group (Figure 6; OR 0.96, 95% CI 0.51–1.79). There
was moderate heterogeneity among the studies included
(I2 = 51%).
3.10. Severe sepsis among neutropenic patients
Mokart et al. investigated neutropenic patients after chemo-
therapy with severe sepsis or septic shock in an ICU in France,
conducting a prospective observational study.34 De-escalation was
performed in 44 patients, whereas 57 patients did not undergo de-
escalation. The ICU mortality was 23%. Six patients died after going
through de-escalation during neutropenia, two patients died de-
escalated after recovering from neutropenia, and 15 patients
without de-escalation also died. De-escalation was not associated
with the hazard of death within the ﬁrst 30 days (HR 0.51, 95% CI
0.20–1.33), or within the 1 year post ICU discharge (HR 1.06, 95% CI
0.54–2.08). (B) for ventilator-associated pneumonia (CI, conﬁdence interval).
Figure 6. Forest plot of 90-day mortality for severe sepsis and septic shock (CI, conﬁdence interval).
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Morel et al. conducted a retrospective observational study in an
ICU of a teaching hospital in France.35 All patients who were
treated with empiric antimicrobials were included irrespective of
the origin and severity of the suspected infection.
De Waele et al. also performed a retrospective observational
study in a surgical ICU in a university hospital in Belgium.36 All
patients receiving more than one dose of meropenem as empirical
therapy were included in the analysis.
Gonzalez et al. conducted a retrospective observational study at
a medical ICU in a university hospital in France.37 A variety of
infections were included in the analysis and there were no
protocols for the administration of empirical antimicrobials.
Meta-analyses of both ICU-mortality and in-hospital mortality
showed no difference between the de-escalation group and the
non-de-escalation group (Figure 7; OR 0.67, 95% CI 0.26–1.73 and
OR 0.85, 95% CI 0.52–1.38, respectively).
3.12. Pneumococcal bacteremia
Cremers et al. conducted a retrospective study on pneumococ-
cal bacteremia at two hospitals in the Netherlands.38 A total of
275 cases were analyzed and the majority of them had
accompanying pneumonia (229 cases, 83.3%). In-hospital mortali-
ty was signiﬁcantly lower in the de-escalation group than in the
non-de-escalation group (6.3% vs. 15.4%, p = 0.021). However, after
adjusting for potential confounders, de-escalation was not
associated with decreased in-hospital mortality (OR 0.55, 95% CI
0.20–1.51, p = 0.242).
3.13. De-escalation from carbapenems
Lew et al. evaluated the effectiveness of de-escalation from
carbapenems at an academic hospital in Singapore.39 A retrospec-
tive observational study was conducted from 2011 to 2012, whenFigure 7. Forest plot of ICU mortality (A) and in-hospital mortality (B) for there was high endemicity of multidrug-resistant Gram-negative
bacteria in the region. Their antimicrobial stewardship program
recommended de-escalation for health care-associated or hospital-
acquired infections upon susceptibility testing results, and they
evaluated data based on acceptance or rejection of their
recommendation. Neither 30-day mortality nor in-hospital mor-
tality differed between the de-escalation group and the non-de-
escalation group (12.3% vs. 14.6%, p = 0.58, and 15.2% vs. 17.7%,
p = 0.58, respectively). The strength of this study was that it
restricted patients to those for whom de-escalation was recom-
mended by the antimicrobial stewardship program team, taking
various factors such as contraindications to certain antimicrobials
into consideration.
For each meta-analysis, no signiﬁcant funnel plot asymmetry
was found (results not shown).
A GRADE evidence proﬁle was produced through quality
assessment (Table 1). The majority of studies included in this
systematic review were of ‘low’ or ‘very low’ quality, mostly
because they were observational in design.
4. Discussion
A total of 23 studies evaluating the effectiveness and safety of
de-escalation therapy for a variety of infections were identiﬁed. For
critical outcomes such as in-hospital mortality, de-escalation
appeared equally effective or even better than therapy that did not
involve de-escalation . Meta-analysis suggested that de-escalation
may improve mortality in both community-acquired and ICU-
acquired pneumonia (Figures 2 and 4). However, the quality of the
studies used in these analyses was generally low.
Despite this, fairly high quality studies were identiﬁed; there
were two RCTs17,32 and one observational study with a propensity
score analysis.31 Although the study by Kim et al. had the problem
of different empirical regimens used in the two groups,17 the RCT
by Leone et al.,32 as well as the propensity score analysis by
Garnacho-Montero et al.,31 suggested that de-escalation afterinfections in the ICU (ICU, intensive care unit; CI, conﬁdence interval).
Table 1
GRADE evidence proﬁle for de-escalation therapy
Quality assessment Number of
patients
De-escalation/
non-de-escalation
Relative
effect
(95% CI)
Quality Importance
Number of
studies [Ref.]
Study design Risk of bias Inconsistency Indirectness Imprecision Other considerations
30-day mortality for community-acquired pneumonia
2 [15,16] Observational
studies
Seriousa Not serious Not serious Not serious All plausible residual
confounding would
reduce the
demonstrated effectb
279 cases/2629 controls OR 0.50 (0.29–0.87) Low Critical
In-hospital mortality for hospital-acquired pneumonia (RCT)
1 [17] Randomized
trials
Seriousc Not serious Not serious Seriousd All plausible residual
confounding would
suggest a spurious
effect, while no effect
was observed
54 cases/55 controls OR 1.41 (0.65–3.05) Moderate Critical
In-hospital mortality for hospital-acquired pneumonia (bacteremic, observational)
1 [18] Observational
studies
Seriousa Not serious Not serious Not serious All plausible residual
confounding would
reduce the
demonstrated effectb
33 cases/27 controls OR 0.29 (0.07–1.24) Low Critical
In-hospital mortality for ICU-associated pneumonia
2 [19,22] Observational
studies
Seriousa Not serious Not serious Not serious All plausible residual
confounding would
reduce the
demonstrated effect
129 cases/82 controls OR 0.34 (0.12–0.68) Low Critical
In-hospital mortality for ventilator-associated pneumonia
3 [23,25,26] Observational
studies
Seriousa Not serious Not serious Not serious All plausible residual
confounding would
reduce the
demonstrated effectb
485 cases/394 controls OR 0.88 (0.54–1.42) Low Critical
28-day mortality for ventilator-associated pneumonia
2 [24,25] Observational
studies
Seriousa Not serious Not serious Not serious All plausible residual
confounding would
reduce the
demonstrated effectb
378 cases/177 controls OR 0.49 (0.07–3.32) Low Critical
In-hospital mortality for bacteremia
1 [27] Observational
studies
Seriousa Not serious Not serious Not serious All plausible residual
confounding would
reduce the
demonstrated effectb
79 cases/122 controls OR 0.25 (0.03–2.10) Low Critical
In-hospital mortality for Gram-negative bacteremia (SPACEs)
1 [28] Observational
studies
Seriousa Not serious Not serious Not serious All plausible residual
confounding would
reduce the
demonstrated effectb
28 cases/11 controls OR 0.07 (0.00–1.52) Low Critical
In-hospital mortality for severe sepsis and septic shock
1 [31] Observational
studies
Not serious Not serious Not serious Not serious All plausible residual
confounding would
suggest a spurious
effect, while no effect
was observede
219 cases/246 controls OR 0.55 (0.32–0.98) Moderate Critical
90-day mortality for severe sepsis and septic shock (RCT)
1 [32] Randomized
trials
Not serious Not serious Not serious Not serious None 59 cases/57 controls HR 1.31 (0.64–2.67) High Critical
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Table 1 (Continued )
Quality assessment Number of
patients
De-escalation/
non-de-escalation
Relative
effect
(95% CI)
Quality Importance
Number of
studies [Ref.]
Study design Risk of bias Inconsistency Indirectness Imprecision Other considerations
90-day mortality for severe sepsis and septic shock (observational study)
1 [32] Observational
studies
Not serious Not serious Not serious Not serious All plausible residual
confounding would
reduce the
demonstrated effecte
219 cases/246 controls OR 0.55 (0.34–0.87) Moderate Critical
30-day mortality for severe sepsis among neutropenic patients
1 [34] Observational
studies
Seriousa Not serious Not serious Not serious All plausible residual
confounding would
reduce the
demonstrated effectb
44 cases/57 controls HR 0.51 (0.20–1.33) Low Critical
ICU mortality for ICU infections
2 [36,37] Observational
studies
Seriousa Not serious Not serious Seriousd All plausible residual
confounding would
reduce the
demonstrated effectb
145 cases/151 controls OR 0.67 (0.26–1.73) Very low Critical
In-hospital mortality for ICU infections
2 [35,37] Observational
studies
Seriousa Not serious Not serious Seriousd All plausible residual
confounding would
reduce the
demonstrated effectb
177 cases/185 controls OR 0.85 (0.52–1.38) Very low Critical
In-hospital mortality for pneumococcal bacteremia
1 [38] Observational
studies
Seriousa Not serious Not serious Not serious All plausible residual
confounding would
reduce the
demonstrated effectb
126 cases/149 controls OR 0.55 (0.20–1.51) Low Critical
30-day mortality after carbapenem use for health care-associated or hospital-acquired infections
1 [39] Observational
studies
Seriousa Not serious Not serious Not serious All plausible residual
confounding would
reduce the
demonstrated effectb
204 cases/96 controls OR 0.82 (0.40–1.65) Low Critical
CI, conﬁdence interval; OR, odds ratio; RCT, randomized controlled trial; ICU, intensive care unit; SPACEs, Serratia, Pseudomonas, Acinetobacter, Citrobacter, and Enterobacter; HR, hazard ratio.
a Observational study.
b De-escalation group could have a better prognosis to begin with.
c Open-label; initial empirical antimicrobials differed between the groups.
d Diagnostic criteria not clear.
e Factors unidentiﬁed in propensity score analysis might exist.
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G. Ohji et al. / International Journal of Infectious Diseases 49 (2016) 71–7978sepsis and septic shock might be clinically useful. These studies
indicated that de-escalation did not impair the mortality outcome
and thus may be an important option to maintain clinical
effectiveness for infections while avoiding the overuse of broad-
spectrum antimicrobials.
A recently published systematic review and meta-analysis
combined studies on infections occurring in the ICU.40 Although
the random-effects model of meta-analysis allows various types of
study to be included, and this may produce statistically signiﬁcant
ﬁndings, the present authors considered it clinically important to
treat different clinical entities differently so that clinicians can
apply the ﬁndings to their own practice. For example, when
managing infectious diseases, clinicians usually treat neutropenic
patients differently from those who are not .41
There are several limitations in these analyses. First, the
overall quality of the studies included in the analyses was not
high. Although the inclusion of observational studies in a
systematic review and meta-analysis is justiﬁable, and may
even improve the quality of the analysis,5,10,42 these should be of
good quality to yield more reliable results. Second, although it
was sought to identify all studies relevant to this systematic
review and meta-analysis, there may be studies that were not
identiﬁed in the thorough search. Third, there are many other
types of infectious disease, such as cholangitis, infective
endocarditis, and septic arthritis; however relevant studies on
these infections were not found. Further RCTs and observational
studies of better quality are needed to overcome these
limitations.
In conclusion, available studies in regard to de-escalation and
its impact on mortality were identiﬁed and it was found that de-
escalation appears safe and effective for certain infectious diseases.
Further studies are needed to conﬁrm these ﬁndings and to apply
them to other types of infection.
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Appendix
Search of MEDLINE via PubMed
#1 (De-escalation) OR (De escalation) OR (Deescalate) OR
(Narrow spectrum) OR (Narrow-spectrum) or (Narrower spec-
trum) OR (Tailoring) OR (Tailor) OR (Downgrading) OR (Discon-
tinue) OR (Discontinuing)
#2 (Anti-Bacterial agents [Mesh]) OR (Antibiotic therapy) OR
(Anti Bacterial) OR (Antibacterial) OR (Anti-Mycobacterial) OR
(Bactericidal) OR (Antifungal agents [Mesh]) OR (Anti-fungal) OR
(Antifungic) OR (Anti-fungic) OR (Fungicides) OR (Chemothera-
pies) OR (Chemotherapy) OR (Drug therapies) OR (Drug therapy
[Mesh]) OR (Pharmacotherapies) OR (Pharmacotherapy)
#3 (Adequacy) OR (Adequate) OR (Extended-spectrum) OR
(Appropriate) OR (Empiric) OR (Empirical) OR (Broad-spectrum)
OR (Broad spectrum)
#1 AND #2 AND #3Search of EMBASE
#1 ‘antiinfective agent[emtree]’ OR ‘anti bacterial’ OR (‘antibi-
otic’ OR ‘antibiotic’/exp) OR antibioitic AND (‘therapy’ OR ‘therapy’/
exp OR therapy) OR (anti AND bacterial) OR antibacterial OR
bactericidal OR ‘anti mycobacterial’ OR (anti AND mycobacterial)
OR antimycobacterial OR ‘antibiotics’ OR ‘antibiotics’/exp OR
antibiotics OR ‘antibiotic’ OR ‘antibiotic’/exp OR antibiotic OR
bacteriocidal OR bacteriocides OR ‘antifungal’ OR ‘antifungal’/exp
OR antifungal OR ‘anti fungal’ OR antifungic OR ‘anti fungic’ OR
fungicides OR chemotherapies OR ‘chemotherapy’ OR ‘chemother-
apy’/exp OR chemotherapy OR (‘drug’ OR ‘drug’/exp OR drug AND
therapies) OR (‘drug’ OR ‘drug’/exp OR drug AND (‘therapy’ OR
‘therapy’/exp OR therapy)) OR pharmacotherapies OR ‘pharmaco-
therapy’ OR ‘pharmacotherapy’/exp OR pharmacotherapy
#2 adequacy OR adequate OR ‘extended spectrum’ OR
appropriate OR empiric OR empirical OR ‘broad spectrum’ OR
(broad AND (‘spectrum’/exp OR spectrum))
#3 narrow AND (‘spectrum’/exp OR spectrum) OR ‘narrow
spectrum’ OR (narrower AND (‘spectrum’/exp OR spectrum)) OR
‘narrower spectrum’ OR ‘narrowered spectrum’ OR (narrowered
AND (‘spectrum’/exp OR spectrum)) OR (de AND escalation) OR
narrowing OR deescalate OR ‘de escalation’ OR ‘adjustment’/exp
OR adjustment OR adjust OR tailoring OR tailored OR tailor OR
downgrading OR discontinue OR discontinuing OR switch$
#1 and #2 and #3
Search of Cochrane Library
#1 de-escalation OR (De escalation) OR Deescalate OR (Narrow
spectrum) OR Narrow-spectrum or (Narrower spectrum) OR
Tailoring OR Tailor OR Downgrading OR Discontinue OR Dis-
continuing
#2 (Anti-Bacterial agents) OR (Antibiotic therapy) OR (Anti
Bacterial) OR Antibacterial OR Anti-Mycobacterial OR Bactericidal
OR (Antifungal agents) OR Anti-fungal OR Antifungic OR Anti-
fungic OR Fungicides OR Chemotherapies OR Chemotherapy OR
(Drug therapies) OR (Drug therapy) OR Pharmacotherapies OR
Pharmacotherapy
#3 Adequacy OR Adequate OR Extended-spectrum OR Appro-
priate OR Empiric OR Empirical OR Broad-spectrum OR (Broad
spectrum)
#1 AND #2 AND #3
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